Tessa Straatmijer, Fiona D M van Schaik, Alexander G L Bodelier, Marijn Visschedijk, Annemarie C de Vries, Cyriel Y Ponsioen, Marieke Pierik, Ad A van Bodegraven, Rachel L West, Nanne K H de Boer, Nidhi Srivastava, Tessa E H Romkens, Jildou Hoekstra, Bas Oldenburg, Gerard Dijkstra, Janneke C van der Woude, Mark Löwenberg, Zlatan Mujagic, Vince B C Biemans, Andrea E van der Meulen-de Jong, Marjolijn Duijvestein
BACKGROUND: Tofacitinib is an oral Janus kinase (JAK) inhibitor and is registered for the treatment of ulcerative colitis (UC). The effectiveness of tofacitinib has been evaluated up to 12 months of treatment. AIM: The aim of this study was to assess the effectiveness and safety of 24 months of tofacitinib use in UC patients in the Netherlands. METHODS: Patients initiating tofacitinib treatment were included in the ICC Registry, a nationwide, observational registry...
January 2023: Alimentary Pharmacology & Therapeutics